All

COVID-19, Flu and RSV Shots − An Epidemiologist Explains Why All Three Matter This Fall

Epidemiologist Annette Regan explains why officials recommend that people get these shots over the coming months.

All

NIH Begins Trial of Experimental Nasal COVID-19 Vaccine

The phase 1 clinical trial to test the safety and immune response of an experimental nasal spray vaccine designed to provide broader protection against emerging COVID-19 variants.

All

COVID-19 Vaccines in Pregnancy Shield Infants for Six Months

An NIH study found that women who receive an mRNA-based COVID-19 vaccination or booster during pregnancy can provide their infants with strong protection against symptomatic COVID-19 infection for at least six months after birth.

WHO Recommendations on COVID-19 Vaccine Composition

by RT Staff | Dec 14, 2023 | Intl' Pharmaceuticals | 0

WHO advises retaining the current COVID-19 vaccine antigen composition, one that uses a monovalent XBB.1.5 as the COVID-19 vaccine antigen.

Maternal COVID-19 Shots Linked to Decrease in Preterm Births

by RT Staff | Nov 29, 2023 | Coronavirus | 0

A new study indicates that COVID-19 vaccination during pregnancy significantly reduced preterm births and NICU admissions, which were elevated during the first two years of the pandemic.

FDA Urges Accurate Dosage of Moderna COVID-19 Vaccine for Children

by RT Staff | Nov 2, 2023 | Coronavirus, Pediatric Care, US Pharmaceuticals | 0

The FDA has become aware that some providers may not realize the Moderna COVID-19 vaccine vial for ages 6 months to 11 years holds more than the 0.25 mL dose.

Moderna Flu-COVID Vaccine Begins Phase 3 Study

by RT Staff | Oct 24, 2023 | Coronavirus, Influenza, US Pharmaceuticals | 0

The first participant has been dosed in a Phase 3 study of Moderna’s Flu-COVID vaccine candidate (mRNA-1083) in the US, according to the company.

Positive Data for Moderna Flu-COVID Vaccine Combo

by RT Staff | Oct 4, 2023 | Coronavirus, Influenza, US Pharmaceuticals | 0

Moderna reported positive interim results from the Phase 1/2 trial of its combination vaccine against influenza and COVID-19.

FDA Authorizes Updated Novavax COVID-19 Vaccine

by RT Staff | Oct 3, 2023 | Coronavirus, Industry & Regulatory News, US Pharmaceuticals | 0

The FDA amended the emergency use authorization of the Novavax COVID-19 vaccine, adjuvanted to include the 2023-2024 formula.

ATS Broadens Vaccine Push with Partnership from Five More Health Systems

by RT Staff | Sep 20, 2023 | Association News, US Pharmaceuticals | 0

The health systems will prioritize improving vaccine rates among high-risk adults with lung disease across different populations.

FDA Approves Updated COVID Vaccines from Pfizer and Moderna

by RT Staff | Sep 11, 2023 | Coronavirus, FDA Approvals, US Pharmaceuticals | 0

The mRNA vaccines are formulated to more closely target currently circulating variants by including a monovalent component that corresponds to the Omicron variant XBB.1.5.

FDA Approves Moderna’s Updated COVID-19 Vaccine

by RT Staff | Sep 11, 2023 | FDA Approvals, US Pharmaceuticals | 0

The FDA approved Moderna’s updated COVID-19 vaccine (Spikevax) for ages 12 years and above, and issued emergency use authorization for children age 6 months through 11 years old.

Pfizer and BioNTech Get Positive EU Opinion for Updated COVID-19 Vaccine

by RT Staff | Aug 30, 2023 | Business News, Coronavirus, Intl' Pharmaceuticals | 0

The companies also filed an application with the FDA requesting approval of their Omicron XBB.1.5-adapted monovalent COVID-19 vaccine for individuals 6 months of age and older.